Trial · NCT03242252
Results by group36
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 36 of 36
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With HbA1c <6.5% at Week 26 | Sotagliflozin 400 mg | 5.7 | percentage of participants | ||
| Percentage of Participants With HbA1c <7.0% at Week 26 | Placebo | 13.5 | percentage of participants | ||
| Percentage of Participants With HbA1c <7.0% at Week 26 | Sotagliflozin 200 mg | 19.4 | percentage of participants | ||
| Percentage of Participants With HbA1c <7.0% at Week 26 | Sotagliflozin 400 mg | 20.8 | percentage of participants | ||
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | Placebo | 78.1 | percentage of participants | ||
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | Sotagliflozin 200 mg | 76.8 | percentage of participants | ||
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | Sotagliflozin 400 mg | 74.2 | percentage of participants | ||
| Percentage of Participants With Hypoglycemic Events | Placebo | Any hypoglycemia | 38.1 | percentage of participants | |
| Percentage of Participants With Hypoglycemic Events | Sotagliflozin 200 mg | Any hypoglycemia | 41.9 | percentage of participants | |
| Percentage of Participants With Hypoglycemic Events | Sotagliflozin 400 mg | Any hypoglycemia | 35.4 | percentage of participants | |
| Percentage of Participants With Hypoglycemic Events | Placebo | Documented symptomatic hypoglycemia | 26.9 | percentage of participants | |
| Percentage of Participants With Hypoglycemic Events | Sotagliflozin 200 mg | Documented symptomatic hypoglycemia | 29.6 | percentage of participants | |
| Percentage of Participants With Hypoglycemic Events | Sotagliflozin 400 mg | Documented symptomatic hypoglycemia | 22.3 | percentage of participants | |
| Percentage of Participants With Hypoglycemic Events | Placebo | Severe or documented symptomatic hypoglycemia | 26.9 | percentage of participants | |
| Percentage of Participants With Hypoglycemic Events | Sotagliflozin 200 mg | Severe or documented symptomatic hypoglycemia | 29.6 | percentage of participants | |
| Percentage of Participants With Hypoglycemic Events | Sotagliflozin 400 mg | Severe or documented symptomatic hypoglycemia | 22.3 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03242252/results?page=2